I-Pazopanib Hydrochloride CAS 635702-64-6 Purity >99.0% (HPLC) API Factory

Incazelo emfushane:

Igama Lekhemikhali: Pazopanib Hydrochloride

I-CAS: 635702-64-6

Ukubukeka: Impushana Emhlophe Ukuya Ephuzi Kancane

Ubumsulwa: >99.0% (HPLC)

I-Tyrosine kinase receptor inhibitor yokwelashwa kwe-renal cell carcinoma ethuthukisiwe noma i-advanced tissue sarcoma

Ikhwalithi ephezulu ye-API, Ukukhiqiza Kwezentengiso

Inquiry: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Ukunikezela Komkhiqizi Ngokuhlanzeka Okuphezulu kanye Nekhwalithi Ezinzile
Igama Lekhemikhali: Pazopanib Hydrochloride
I-CAS: 635702-64-6
I-Tyrosine kinase receptor inhibitor yokwelashwa kwe-renal cell carcinoma ethuthukisiwe noma i-soft tissue sarcoma ethuthukisiwe ethole i-chemotherapy yangaphambili.
Ikhwalithi ephezulu ye-API, Ukukhiqiza Kwezentengiso

Chemical Properties:

Igama Lekhemikhali	I-Pazopanib Hydrochloride
Omqondofana	I-Pazopanib HCl;I-GW786034 HCl;I-Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
Inombolo ye-CAS	635702-64-6
Inombolo yeCAT	I-RF-API93
Isimo Sesitoko	Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu
I-Molecular Formula	I-C21H23N7O2S.ClH
Isisindo samangqamuzana	473.987
Ukuncibilika	I-DMSO
I-Melting Point	300.0~304.0℃
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	Impushana Emhlophe Kuya Ephuzi Kancane
Ukuhlonza	I-spectrum yokumuncwa kwe-infraed yesampula yokuhlola ihambisana naleyo yezinga
Izinsalela ekushiseni	≤0.50%
Noma yikuphi Ukungcola Komuntu Ngamunye	≤0.30%
Ukungcola Okuphelele	≤1.50%
Izinsimbi Ezisindayo	≤10ppm
Ukuhlanzeka / Indlela Yokuhlaziya	≥99.0% (HPLC)
Izinga Lokuhlola	I-Enterprise Standard
Ukusetshenziswa	I-API, i-Tyrosine kinase receptor inhibitor

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, isigubhu seCardboard, 25kg/Drum, noma ngokwezidingo zekhasimende.

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.

Izinzuzo:

I-FAQ:

Isicelo:

I-Pazopanib Hydrochloride (CAS 635702-64-6) iyi-multi-tyrosine kinase inhibitor ye-vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR) -α kanye - β, i-fibroblast growth factor receptor (FGFR)-1 kanye -3, i-cytokine receptor (Kit), i-interleukin-2 receptor-inducible T-cell kinase (Itk), i-lymphocyte-specific protein tyrosine kinase (Lck), kanye ne-transmembrane glycoprotein receptor tyrosine i-kinase (cFms).I-In vitro, i-zopanib inhibited ligand-induced autophosphorylation ye-VEGFR-2, Kit, ne-PDGFR-beta receptors.Ngo-vivo, i-zopanib ivimbele i-VEGF-induced phosphorylation ye-VEGF-2 emaphashini egundane, i-angiogenesis kumodeli yegundane, kanye nokukhula kwamanye ama-xenografts wesimila kumagundane.Yagunyazwa i-renal cell carcinoma yi-US Food and Drug Administration ngo-2009 futhi imakethwa ngaphansi kwegama lokuhweba elithi Votrient ngumkhiqizi womuthi, i-GlaxoSmithKline.I-Votrient iyi-kinase inhibitor ekhonjiswe ukwelashwa kweziguli ezine: 1) i-advanced renal cell carcinoma.2) izicubu ezithambile ze-sarcoma ezithole ukwelashwa ngamakhemikhali ngaphambili.